ReviewNature reviews. Nephrology2016
Biologics for the treatment of autoimmune renal diseases.
Review in Nature reviews. Nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 52 citations in OpenAlex.
- Inflammatory bowel disease and renal disorders: from clinical associations to shared mechanisms and management strategies.Frontiers in immunology · 2026Review
- Biological targeted therapy for lupus nephritis-the role of BLYS and APRIL.Renal failure · 2025Review
- BAFF in autoimmune kidney diseases: pathogenic pathways, biomarker potential, and therapeutic horizons.Renal failure · 2025Review
- Role of Mast Cells and Their Mediators in Chronic Kidney Diseases.International journal of molecular sciences · 2025Review
- Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights.The American journal of case reports · 2025Article
- mIgM-mediated splenic marginal zone B cells targeting of folic acid for immunological evasion.Acta pharmaceutica Sinica. B · 2024Article
- Current progress in CAR-based therapy for kidney disease.Frontiers in immunology · 2024Review
- Telitacicept for autoimmune nephropathy.Frontiers in immunology · 2023Review
- Role of the adaptive immune system in diabetic kidney disease.Journal of diabetes investigation · 2022Review
- C3-Epimer of 25-Hydroxyvitamin D3 as a Superior Marker for Predicting the Severity of Chronic Kidney Disease in Rheumatoid Arthritis Patients.Oxidative medicine and cellular longevity · 2022Article
- Multi-Target Drugs for Kidney Diseases.Kidney360 · 2021Article
- Ixekizumab May Improve Renal Function in Psoriasis.Healthcare (Basel, Switzerland) · 2021Article
- A single-cell survey of the human glomerulonephritis.Journal of cellular and molecular medicine · 2021Article
- A novel monoclonal antibody against human B7-1 protects against chronic graft-vs.-host disease in a murine lupus nephritis model.Experimental and therapeutic medicine · 2020Article
- ANCA-associated vasculitis.Nature reviews. Disease primers · 2020Review
- A highly potent lymphatic system-targeting nanoparticle cyclosporine prevents glomerulonephritis in mouse model of lupus.Science advances · 2020Article
- Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model.Kidney international · 2020Article
- Rituximab use in adult glomerulopathies and its rationale.Jornal brasileiro de nefrologia · 2020Review
- Co-inhibitory Receptor Signaling in T-Cell-Mediated Autoimmune Glomerulonephritis.Frontiers in medicine · 2020Review
- Transplantation of Mouse Induced Pluripotent Stem Cell-Derived Podocytes in a Mouse Model of Membranous Nephropathy Attenuates Proteinuria.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biological therapeutics (biologics) that target autoimmune responses and inflammatory injury pathways have a marked beneficial impact on the management of many chronic diseases, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and ankylosing spondylitis. Accumulating data suggest that a growing number of renal diseases result from autoimmune injury - including lupus nephritis, IgA nephropathy, anti-neutrophil cytoplasmic antibody-associated glomerulonephritis, autoimmune (formerly idiopathic) membranous nephropathy, anti-glomerular basement membrane glomerulonephritis, and C3 nephropathy - and one can speculate that biologics might also be applicable to these diseases. As many autoimmune renal diseases are relatively uncommon, with long natural histories and diverse outcomes, clinical trials that aim to validate potentially useful biologics are difficult to design and/or perform. Some excellent consortia are undertaking cohort studies and clinical trials, but more multicentre international collaborations are needed to advance the introduction of new biologics to patients with autoimmune renal disorders. This Review discusses the key molecules that direct injurious inflammation and the biologics that are available to modulate them. The opportunities and challenges for the introduction of relevant biologics into treatment protocols for autoimmune renal diseases are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.